Activity of Moxifloxacin Against Ofloxacin-ResistantMycobacterium Tuberculosis: A Study of Cross-Resistance Between Ofloxacin and Moxifloxacin
Abstract
Background : Moxifloxacin is an 8-methoxyquinolone compound which has been shown to have the best activity of the quinolones against M. tuberculosis but there is no literature showing the rate of cross-resistance between moxifloxacin and the other quinolones such as ofloxacin.Therefore, we tested the activity of moxifloxacin against ofloxacin resistant M. tuberculosis by a study of cross-resistance.Methods : We tested MIC's of moxifloxacin and ofloxacin by proportion method against 34 M. tuberculosis isolates showing resistance against ofloxacin at 2.5㎍/㎖ concentration and 13 ofloxacin susceptible isolates from specimens submitted to clinical laboratory of National Masan Hospital from March 2003 to March 2004.Results : For ofloxacin susceptible isolates, MIC50 and MIC90 of ofloxacin were all 1.25㎍/㎖, and MIC50 and MIC90 of moxifloxacin were 0.31㎍/㎖ and 0.63㎍/㎖ respectively.For ofloxacin resistant isolates, MIC50 of ofloxacin was over 10㎍/㎖ and MIC50 of moxifloxacin was 5㎍/㎖ ,MIC90 of ofloxacin and moxifloxacin were all over 10㎍/㎖.The rate of cross-resistance between the two was 67.6%(23/34) at 2.5㎍/㎖ concentration.Conclusions : Moxifloxacin showed activity against 82.4%(28/34) of ofloxacin resistant M. tuberculosis at 10㎍/㎖, but more studies are needed so that moxifloxacin will be used for patient with multi-drug resistant tuberculosis including oflokacin resistance.(
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.